Home
Neos Therapeutics

Neos Therapeutics Market Share Analysis for November 2025

Health > Biotechnology and Pharmaceuticals

Domainneostx.com

Year Founded2008

Employees51 - 200

Annual Revenue$50M - $75M

Neos Therapeutics

Neos Therapeutics (including company regionals)

neostx.com

See more website traffic and engagement information

Neos Therapeutics Revenue up to November 2025 is 50M - 75M

revenue generated by Neos Therapeutics top domains

Neos Therapeutics top domains revenue over 3 years

Revenue for Neos Therapeutics top domains

neostx.com50M - 75M

See more with Sales Intelligence

Total visits to Neos Therapeutics's top domains

Understand Neos Therapeutics market share and potential market reach.

Total visits last 3 months

No Data to Display

Avg. visit duration in Neos Therapeutics's top domains

Analyze Neos Therapeutics engagement metrics.

Average visit duration last 3 months

No Data to Display

Avg. pageviews on Neos Therapeutics's top domains

See how Neos Therapeutics keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

No Data to Display

Neos Therapeutics top competitors by domain

Top similar sites in November 2025, ranked by their affinity

ropack.comCompany NameRopack, Inc.Employees201 - 500HQCanada, MontréalAnnual revenue$50M - $75MTotal visits570Health > Biotechnology and Pharmaceuticals

Top technologies used by Neos Therapeutics

These are the website technologies, by industry, used by Neos Therapeutics top domains

Widget (4)

Twemoji

Mobile (2)

Meta Viewport

Audio Video Media (1)

Vimeo

Content Management System (1)

WordPress

More Technologies

5

See all

News & Signals from Neos Therapeutics

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsAytu Consumer Health, Inc. partners with Neostx.Aytu BioScience (NASDAQ: AYTU ) announces the closing of its $44.9M merger with Neos Therapeutics, with Neos merging with a wholly-owned subsidiary of Aytu.

NewsNeostx has issues with violated the federal securities laws.Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of Neos Therapeutics, Inc. (NASDAQ: NEOS) breached their fiduciary duties or violated the federal securities laws in connection with the company’s acquisition by Aytu BioScience, Inc. (NASDAQ: AYTU).

NewsNeostx has issues with possible breaches of fiduciary duty and other violations of law.WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Neos Therapeutics, Inc. ("NEOS" or the "Company") (NASDAQ: NEOS ) in connection with the proposed acquisition of the Company by Aytu BioScience, Inc. ("Aytu") (NASDAQ: AYTU ).